Valuation Northwest Biotherapeutics, Inc. Börse Stuttgart

Stocks

Market Closed - Börse Stuttgart Other stock markets 20:56:12 14/07/2026 BST			5-day change	1st Jan Change
0.1500 ^EUR	-6.25%		-6.25%	-27.18%

07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
05-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2024	2025	2026	2027
Market Cap ¹	364	358.4	299	-
Change	-	-1.53%	-16.57%	-
Enterprise Value (EV) ¹	364	358.4	395.1	424
Change	-	-1.53%	10.24%	7.3%
P/E	-3.93x	-5.72x	-	-
PBR	-	-	-	-
PEG	-	0.1x	-	-
Capitalization / Revenue	-	-	-	7.68x
EV / Revenue	-	-	-	10.9x
EV / EBITDA	-	-	-	-
EV / EBIT	-	-	-5.87x	-8.94x
EV / FCF	-	-	-7.75x	-10.4x
FCF Yield	-	-	-12.9%	-9.61%
Dividend per Share ²	-	-	-	-
Rate of return	-	-	-	-
EPS ²	-0.07	-0.04	-	-
Distribution rate	-	-	-	-
Net sales ¹	-	-	-	38.93
EBITDA	-	-	-	-
EBIT ¹	-	-	-67.3	-47.4
Net income	-85.19	-61.48	-	-
Net Debt ¹	-	-	96.08	124.9
Reference price ²	0.2748	0.2288	0.1803	0.1803
Nbr of stocks (in thousands)	1,324,666	1,566,728	1,658,458	-
Announcement Date	31/03/25	15/04/26	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
WUXI APPTEC CO., LTD.	20.06x	6.16x	13.43x	1.6%	53.54B
ARGENX SE	32.54x	8.23x	25.52x	0.06%	54.18B
INSMED INCORPORATED	-41.84x	13.68x	-39.9x	-.--%	23.66B
BIONTECH SE	-17.97x	4.21x	-7.37x	-.--%	22.78B
WUXI BIOLOGICS (CAYMAN) INC.	24.64x	4.81x	12.68x	-.--%	19.54B
GENMAB A/S	25.1x	4.86x	15.83x	-.--%	17.82B
PHARMAESSENTIA CORPORATION	48x	19.5x	50.21x	0.08%	16.01B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-526.19x	37.05x	-4130.99x	-.--%	15.37B
EXELIXIS, INC.	17.61x	5.12x	11.91x	-.--%	14.09B
Average	-46.45x	11.51x	-449.85x	0.19%	26.33B
Weighted average by Cap.	-19.85x	9.83x	-257.40x	0.38%